Search the database for deliberate release of GM medicinal products
Displaying 1 - 5 of 5
|EU record number
|Company / Sponsor
|Only notified under the "contained use" procedure. Dossier submitted on 20/08/2018.
|A Phase I/II study of the safety and efficacy of a single dose of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells in subjects with severe sickle disease
|CRISPR Therapeutic AG
|Modified cells expressing Hemoglobin F (HbF)
|Clinical trial evaluating the safety and efficacy of intracoronary administration of MYDICAR (AAV1/SERCA2a) in subjects with heart failure
|Human SERCA2a:CA++ pump involved in the regulation of heart contraction/relaxation cycle
|Only notified under the "contained use" procedure. Dossier submitted on 23/04/2012.
|Randomized Phase III of haploidentical HCT with or without an add back strategy of HSV-Tk donor lymphocytes in patients with high risk acute leukemia
|-Thymidine Kinase (HSV-Tk) - selection marker
|Only notified under the "contained use" procedure. Dossier submitted on 13/10/2000.
|A phase III open-label, comparative, multicentre trials to test the concept of durable virologic suppression in subjects with primary HIV-1 infection after intensive induction of quadruple HAART followed by double-blind randomization to HIV vaccination wi
|Only notified under the "contained use" procedure. Dossier submitted on 26/03/1998.
|Pilot study of immunization with recombinant canarypox virus vCP1469A expressing the MAGE-1.A1 and MAGE-3.A1 cytolytic T lymphocytes epitopes in patients with malignant melanoma, non-small cell lung carcinoma, head-and-neck squamous cell carcinoma, esopha
|Pasteur Mérieux Connaught
|HLA-A1 restricted CTL epitope of MAGE-1 and MAGE-3 genes